NuVasive (Nasdaq:NUVA) - Hisse Senedi Fiyatı, Haberler ve Analizler

NUVA Stoklara Genel Bakış

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. Daha fazla detay

NUVA temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	1/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 47.4% daha düşük bir oranda işlem görüyor

Kazançların yılda 46.22% oranında artması öngörülüyor

Bu yıl karlı hale geldi

Analistler hisse senedi fiyatının 23.3% oranında artacağı konusunda hemfikir

Risk Analizi

Borç işletme nakit akışı tarafından iyi karşılanmıyor

Finansal sonuçları etkileyen büyük tek seferlik kalemler

NuVasive, Inc. Rakipler

CONMED

NYSE:CNMD

US$2.2b

LeMaitre Vascular

NasdaqGM:LMAT

US$2.3b

LivaNova

NasdaqGS:LIVN

US$2.7b

InMode

NasdaqGS:INMD

US$1.5b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti NuVasive
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$39.75
52 Haftanın En Yüksek Seviyesi	US$49.53
52 Haftanın En Düşük Seviyesi	US$35.17
Beta	1.07
11 Aylık Değişim	-0.63%
3 Aylık Değişim	0.84%
1 Yıllık Değişim	-8.30%
33 Yıllık Değişim	-22.24%
5 Yıllık Değişim	-42.71%
Halka arzdan bu yana değişim	248.68%

Son Haberler & Güncellemeler

Recent updates

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Apr 18

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

Jan 24

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Dec 31

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Dec 05

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Nov 13

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

Aug 03

NuVasive: Industry Tailwinds More Than Fairly Priced

Jun 13

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jun 01

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

May 11

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Apr 20

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

Mar 30

NuVasive's Turnaround Story Needs A Boost From Better Results

Mar 01

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Dec 28

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

Dec 02

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Nov 11

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Oct 21

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Sep 29

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

Aug 18

NuVasive Still Getting No Love With COVID-19 And Competitive Worries

Aug 12

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Jul 27

Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Jun 17

Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

May 30

Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

May 12

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Mar 30

Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

Mar 09

Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

Feb 16

A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jan 26

NuVasive stock gains on study results of its X360 surgery approach

Jan 06

What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Jan 05

Hissedar Getirileri

	NUVA	US Medical Equipment	US Pazar
7D	1.5%	1.7%	0.3%
1Y	-8.3%	21.4%	31.1%

Getiri vs. Endüstri: NUVA geçen yıl % 21.4 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: NUVA geçen yıl % 31.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is NUVA's price volatile compared to industry and market?
NUVA volatility
NUVA Average Weekly Movement	3.8%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: NUVA son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: NUVA 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1997	3,000	Chris Barry	www.nuvasive.com

NuVasive, Inc. Temel Bilgiler Özeti

NuVasive'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
NUVA temel i̇stati̇sti̇kler
Piyasa değeri	US$2.08b
Kazançlar(TTM)	US$28.45m
Gelir(TTM)	US$1.23b

73.3x

F/K Oranı

1.7x

P/S Oranı

NUVA aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
NUVA gelir tablosu (TTM)
Gelir	US$1.23b
Gelir Maliyeti	US$347.50m
Brüt Kâr	US$878.73m
Diğer Giderler	US$850.28m
Kazançlar	US$28.45m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.54
Brüt Marj	71.66%
Net Kâr Marjı	2.32%
Borç/Özkaynak Oranı	89.1%

NUVA uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

NUVA Stoklara Genel Bakış

Ödüller

Risk Analizi

NuVasive, Inc. Rakipler

NYSE:CNMD

US$2.2b

NasdaqGM:LMAT

US$2.3b

NasdaqGS:LIVN

US$2.7b

NasdaqGS:INMD

US$1.5b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

NuVasive Files Form 15

NuVasive, Inc.(NasdaqGS:NUVA) dropped from NASDAQ Composite Index

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Consensus EPS estimates fall by 19%

New minor risk - Earnings quality

Recent updates

NuVasive Files Form 15

NuVasive, Inc.(NasdaqGS:NUVA) dropped from NASDAQ Composite Index

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Consensus EPS estimates fall by 19%

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

NuVasive, Inc. Provides Sales Guidance for the Full Year 2023

NuVasive, Inc. to Report Q2, 2023 Results on Aug 02, 2023

NuVasive, Inc. Announces Resignation of Marc Rosenbaum as Vice President, Corporate Controller and Chief Accounting Officer

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

NuVasive, Inc. Provides Sales Guidance for the Year 2023

NuVasive, Inc., Annual General Meeting, Jun 09, 2023

NuVasive, Inc. to Report Q1, 2023 Results on May 10, 2023

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

CEO & Director exercised options and sold US$491k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Globus Medical, Inc. (NYSE:GMED) entered into a definitive agreement to acquire NuVasive, Inc. (NasdaqGS:NUVA) for $3.1 billion.

NuVasive, Inc. to Report Q4, 2022 Results on Feb 22, 2023

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Price target decreased to US$49.25

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

NuVasive, Inc. Revises Earnings Guidance for the Year 2022

NuVasive, Inc. Launches Tube System and Excavation Micro for Posterior Spine Surgery

NuVasive, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Price target decreased to US$56.00

Nuvasive Launches Reline Cervical for Posterior Cervical Fusion as Part of the C360 Portfolio

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

NuVasive Likely Undervalued, But It's Hard To Find Catalysts

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

NuVasive, Inc. Announces Departure of Massimo Calafiore as Executive Vice President and Chief Commercial Officer, Effective August 31, 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NuVasive, Inc. Revises Earnings Guidance for the Full Year of 2022

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

NuVasive, Inc. to Report Q2, 2022 Results on Aug 03, 2022

NuVasive: Industry Tailwinds More Than Fairly Priced

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

NuVasive, Inc. Announces Management Changes

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Now 21% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

NuVasive, Inc. Revises Earnings Guidance for the Full Year of 2022

NuVasive, Inc. to Report Q1, 2022 Results on May 04, 2022

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

NuVasive, Inc., Annual General Meeting, May 11, 2022

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

NuVasive's Turnaround Story Needs A Boost From Better Results

Full year 2021 earnings: EPS exceeds analyst expectations

NuVasive, Inc. Provides Earnings Guidance for the Full Year 2022

NuVasive, Inc. to Report Q4, 2021 Results on Feb 23, 2022

NuVasive, Inc. Appoints Andrew C. Morton as Senior Vice President and Chief Human Resources Officer, Effective February 7, 2022

Nuvasive Receives FDA Clearance for Expanded Indications of Use for Attrax Putty with Thoracolumbar Interbody Portfolio

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Price target decreased to US$66.19

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?